Cellebrite Files 6-K for Q4 2023 Results
Ticker: CLBT · Form: 6-K · Filed: Feb 15, 2024 · CIK: 1854587
| Field | Detail |
|---|---|
| Company | Cellebrite Di Ltd. (CLBT) |
| Form Type | 6-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, quarterly-results, foreign-issuer
TL;DR
**Cellebrite just dropped its Q4 2023 results, so expect some movement.**
AI Summary
Cellebrite DI Ltd. filed a 6-K on February 15, 2024, announcing its Fourth Quarter 2023 results via a press release titled "Cellebrite Announces Fourth Quarter 2023 Results." This filing incorporates the GAAP financial statements from the press release by reference. The company, a foreign private issuer, maintains its principal executive office at 94 Shlomo Shmelzer Road, Petah Tikva 4970602, Israel.
Why It Matters
This filing provides investors with the latest financial performance data for Cellebrite DI Ltd., crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer reporting quarterly results, indicating standard operational transparency.
Key Players & Entities
- Cellebrite DI Ltd. (company) — Registrant and issuer of press release
- February 15, 2024 (date) — Date of press release and 6-K filing
- Fourth Quarter 2023 (date) — Period for which results are announced
- 001-40772 (other) — Commission File Number
FAQ
What is the purpose of this 6-K filing by Cellebrite DI Ltd.?
The purpose of this 6-K filing is to furnish a press release titled "Cellebrite Announces Fourth Quarter 2023 Results" issued on February 15, 2024, and to incorporate its GAAP financial statements by reference.
When was the press release regarding the Fourth Quarter 2023 results issued?
The press release titled "Cellebrite Announces Fourth Quarter 2023 Results" was issued on February 15, 2024.
What financial information is included in this 6-K filing?
The 6-K filing incorporates by reference the GAAP financial statements tables contained in the press release attached as Exhibit 99.1.
Is Cellebrite DI Ltd. a domestic or foreign private issuer?
Cellebrite DI Ltd. is a foreign private issuer, as indicated by its filing under Form 20-F and its address in Israel.
What is the principal executive office address of Cellebrite DI Ltd.?
The principal executive office of Cellebrite DI Ltd. is located at 94 Shlomo Shmelzer Road, Petah Tikva 4970602, Israel.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-02-15 07:15:11
Filing Documents
- ea193804-6k_cellebrite.htm (6-K) — 13KB
- ea193804ex99-1_cellebrite.htm (EX-99.1) — 239KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-24-014313.txt ( ) — 265KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellebrite DI Ltd. Date: February 15, 2024 By: /s/ Dana Gerner Dana Gerner Chief Financial Officer 3